Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab

HLA-DR is under investigation as a target for monoclonal antibody (mAb) therapy of malignancies. Here we describe a humanized IgG4 form of the anti-HLA-DR mAb L243, hL243γ4P (IMMU-114), generated to provide an agent with selectivity toward neoplastic cells that can kill without complement-dependent...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Stein, Rhona, Qu, Zhengxing, Chen, Susan, Solis, David, Hansen, Hans J., Goldenberg, David M.
Formato: Artigo
Idioma:Inglês
Publicado: © 2006 by The American Society of Hematology 2006
Assuntos:
Neoplasia
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895595/
https://ncbi.nlm.nih.gov/pubmed/16778139
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-04-017921
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares